Medicare Price Negotiation Savings Would Rise To $101Bn With Revisions To Legislation – CBO
Latest version of Medicare price negotiation and price inflation rebate provisions are expected to lower federal government costs by about $200bn over 10 years.
You may also be interested in...
Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.
Merck & Co. CEO Rob Davis, Regeneron president George Yancopoulos, Pfizer R&D president Mikael Dolsten and others weighed in at the Galien Forum on the potential impact of the US Inflation Reduction Act on innovation.
Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.